Orifarm is evolving into a “much more traditional manufacturing pharmaceutical company” after acquiring a portfolio of select over the counter and prescription pharma products sold in Europe from Takeda for €615 million
The acquisition, the largest in the Danish company’s history, allows Orifarm to future-proof its business by strengthening the company’s core business areas: parallel imported pharmaceuticals, over the-counter pharmaceuticals, and prescription generic pharmaceuticals.
The acquisition will reinforce Orifarm’s position in its key markets and expand its geographic reach to new markets, strengthening its position for the long-term. The future sales and production of over-the-counter and prescription pharmaceuticals will become equally important, the company said.
The products acquired from Takeda are a well-known and recognised portfolio across their key geographies, with significant brand recognition amongst pharmacists and consumers.
It includes approximately 110 pharmaceuticals and dietary supplements, including well-known brands like Pamol, Kodimagnyl, and Zymelin.
CEO Erik Sanberg said the deal is “a gigantic transaction for Orifarm and a gamechanger for Orifarm as a company.
“We will grow to a greater extent into a much more traditional manufacturing pharmaceutical company, and with the acquisition of both the line of products and two further manufacturing sites, we will be able to control a larger part of our value chain.”